CDK Global, Inc. CDK
Set alert
As of Apr 24, 3:47 PM ET
52-week range unavailable
- Open
- 54.82
- Prev close
- 54.76
- Mkt cap
- 6.39B
- Vol
- 16.77M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 1.10%
More statistics
- Low
- 54.75
- High
- 54.87
- Forward P/E
- 16.95
- Beta
- 1.02
- Short ratio
- 2.39
- Inst. own
- 92.56%
- Dividend
- 0.60
- Ex-div date
- Jun 15, 2022
- Earnings
- Aug 16, 2022
- 50-d avg
- 54.47
- 200-d avg
- 47.41
- 1y target
- 57.50
Key statistics
- Market cap
- 6.39B
- Enterprise value
- 8.07B
- Trailing P/E
- 28.08
- Forward P/E
- 16.95
- PEG ratio
- 1.87
- Price / sales
- 3.64
- Price / book
- 14.76
- EPS (TTM)
- 1.95
- Beta
- 1.02
- Dividend yield
- 1.10%
- Payout ratio
- 30.77%
- Profit margin
- 14.28%
- Revenue (TTM)
- 1.76B
- Revenue growth
- 6.10%
- Free cash flow
- 169.89M
- Total cash
- 120.30M
- Total debt
- 1.79B
- Return on equity
- 53.35%
- Shares outstanding
- 116.70M
- Short % of float
- 3.80%
- 50-day average
- 54.47
- 200-day average
- 47.41
Analyst view
Consensus: strong buy
- Strong buy3
- Buy1
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 16, 2022
Expected Aug 16, 2022. Consensus EPS estimate 0.64.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 16, 2022 | Jun 1, 2022 | 0.67 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | 0.74 | — | — | — |
| Feb 3, 2022 | Dec 1, 2021 | 0.65 | — | — | — |
| Nov 2, 2021 | Sep 1, 2021 | 0.67 | — | — | — |
| Aug 17, 2021 | Jun 1, 2021 | 0.67 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | 0.68 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2021 | Morgan Stanley | down | Overweight | Equal-Weight |
| Aug 18, 2021 | Morgan Stanley | main | — | Overweight |
| Aug 5, 2020 | Morgan Stanley | main | — | Overweight |
| Jun 8, 2020 | Morgan Stanley | up | Equal-Weight | Overweight |
| May 6, 2020 | Morgan Stanley | main | — | Equal-Weight |
| Apr 8, 2020 | Wells Fargo | main | — | Overweight |
About CDK Global, Inc.
CDK Global, Inc., together with its subsidiaries, provides integrated data and technology solutions to the automotive, heavy truck, recreation, and heavy equipment industries in the United States and internationally. It offers subscription-based software and technology solutions to automotive retailers, as well as to retailers and manufacturers of heavy trucks, construction and agricultural equipment, motorcycles, boats, and other marine and recreational vehicles. The company's flagship Dealer Management System provides software solutions that facilitates the sale of new and used vehicles, consumer financing, repair and maintenance services, and vehicle and parts inventory management. It also provides a portfolio of layered software applications and services to address the needs of automotive retail workflows. In addition, the company offers data management and business intelligence solutions to automotive retailers and original equipment manufacturers through its Neuron intelligent data platform. Further, it offers professional services, custom programming, consulting, implementation, and training solutions, as well as customer support solutions. The company serves approximately 15,000 retail locations. CDK Global, Inc. was incorporated in 2014 and is headquartered in Hoffman Estates, Illinois.
- Sector
- Technology
- Industry
- Software—Application
- Country
- United States
- Website
- cdkglobal.com
News
- BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
- ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
- CDK Global Names Sudhakar Ramakrishna President and CEO
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
- Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
- Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
- Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
- Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
- Tekion Files Lawsuit Against CDK Global's Anticompetitive Practices
- Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Your note
Sign in to keep a note on CDK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRUN LESLIE A | Director | Stock Award(Grant) | Nov 14, 2021 | 61,762 |
| BRUNZ LEE J | General Counsel | Stock Award(Grant) | Sep 15, 2021 | 87,183 |
| BYRNE AMY W | Officer | Stock Award(Grant) | Jul 5, 2022 | 0 |
| DEESE WILLIE A | Director | Stock Award(Grant) | Nov 14, 2021 | 31,684 |
| HILLMAN AMY J | Director | Stock Award(Grant) | Nov 14, 2021 | 38,819 |
| MILES STEPHEN A | Director | Stock Award(Grant) | Nov 14, 2021 | 39,520 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 19.08% | 22,262,032 | 1.22B | Mar 30, 2022 |
| Vanguard Group, Inc. (The) | 9.58% | 11,185,105 | 612.50M | Mar 30, 2022 |
| Harris Associates L.P. | 5.71% | 6,667,131 | 365.09M | Mar 30, 2022 |
| Clarkston Capital Partners LLC | 5.15% | 6,011,468 | 329.19M | Mar 30, 2022 |
| Invesco Ltd. | 4.30% | 5,016,301 | 274.69M | Mar 30, 2022 |
| State Street Corporation | 2.78% | 3,239,284 | 177.38M | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Equity Dividend Fund | 4.63% | 5,408,057 | 296.15M | Apr 29, 2022 |
| Vanguard Total Stock Market Index Fund | 2.88% | 3,360,031 | 184.00M | Mar 30, 2022 |
| iShares Core S&P Midcap ETF | 2.86% | 3,342,075 | 183.01M | May 30, 2022 |
| Vanguard Small-Cap Index Fund | 2.51% | 2,928,200 | 160.35M | Mar 30, 2022 |
| Invesco Comstock Fd | 2.22% | 2,592,056 | 141.94M | Jan 30, 2022 |
| Vanguard Small Cap Value Index Fund | 1.64% | 1,916,877 | 104.97M | Mar 30, 2022 |